- Company will host earnings conference call and webcast

Amsterdam, the Netherlands and Holzgerlingen, Germany, August 01, 2016 -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it will publish its financial results for the first six months ended on June 30, 2016, on August 19, 2016. In addition, the Company will host a public earnings conference call and webcast on August 19, 2016, at 03:00 pm CET / 09:00 am EST to present the H1 2016 financial results, highlight the most important events and provide an outlook for the second half of 2016 and beyond.

The conference call will be supplemented by a presentation, which can be accessed during the call at http://www.curetis.com/en/investors/financial-reports-and-conferences/financial-reports.html through the participants` passcode curetis0816. The live webcast and a replay will be available at http://curetis190816-live.audio-webcast.com.

To access the call, please dial the following numbers using the passcode 93120684#

Germany: +49 692 222 290 43

UK: +44 203 009 2452

US: +1 855 402 7766

For further international dial-in numbers, please open the following link: http://events.arkadin.com/ev/docs/International Access Numbers_ UKFELBRI1_SU7.pdf

The full half-year financial report 2016 will be available as of August 19, 2016, at http://www.curetis.com/en/investors/financial-reports-and-conferences/financial-reports.html

Disclaimer

CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.

###

About Curetis

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.